Discovery of (R)-2-Amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic Acid and Congeners As Highly Potent Inhibitors of Human Arginases I and II for Treatment of Myocardial Reperfusion Injury

被引:70
作者
Van Zandt, Michael C. [1 ]
Whitehouse, Darren L. [1 ]
Golebiowski, Adam [1 ]
Ji, Min Koo [1 ]
Zhang, Mingbao [1 ]
Beckett, R. Paul [1 ]
Jagdmann, G. Erik [1 ]
Ryder, Todd R. [1 ]
Sheeler, Ryan [1 ]
Andreoli, Monica [1 ]
Conway, Bruce [1 ]
Mahboubi, Keyvan [1 ]
D'Angelo, Gerard [1 ]
Mitschler, Andre [2 ]
Cousido-Siah, Alexandra [2 ]
Ruiz, Francesc X. [2 ]
Howard, Eduardo I. [2 ,3 ]
Podjarny, Alberto D. [2 ]
Schroeter, Hagen [4 ]
机构
[1] Inst Pharmaceut Discovery LLC, Branford, CT 06405 USA
[2] Univ Strasbourg, CNRS, INSERM, Dept Integrat Biol,IGBMC, F-67404 Illkirch Graffenstaden, France
[3] UNLP, CONICET, IFLYSIB, La Plata, Buenos Aires, Argentina
[4] Mars Inc, Mclean, VA 22101 USA
关键词
BINUCLEAR MANGANESE CLUSTER; CRYSTAL-STRUCTURE; APOPTOSIS;
D O I
10.1021/jm400014c
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Recent efforts to identify treatments for myocardial ischemia reperfusion injury have resulted in the discovery of a novel series of highly potent alpha,alpha-disubstituted amino acid-based arginase inhibitors. The lead candidate, (R)-2-amino-6-borono-2-(2-(piperidin-1-yl)ethyl)hexanoic acid, compound 9, inhibits human arginases I and II with IC(50)s of 223 and 509 nM, respectively, and is active in a recombinant cellular assay overexpressing human arginase I (CHO cells). It is 28% orally bioavailable and significantly reduces the infarct size in a rat model of myocardial ischemia/reperfusion injury. Herein, we report the design, synthesis, and structure activity relationships (SAR) for this novel series of inhibitors along with pharmacokinetic and in vivo efficacy data for compound 9 and X-ray crystallography data for selected lead compounds cocrystallized with arginases I and II.
引用
收藏
页码:2568 / 2580
页数:13
相关论文
empty
未找到相关数据